Beyond Achondroplasia

Growing together with Clara

October 20, 2017
by inesp.alves

Recruitment in clinical trials

The following document, shared by BioMarin in September 2017, is a clarification on the ongoing clinical trials for achondroplasia and was released for associations and families: BioMarin Achondroplasia Programme Update 20Sept17 It is important to mention that families interested in … Continue reading

November 7, 2016
by inesp.alves
1 Comment

Conference on achondroplasia

In a collaboration initiative between ALPE Foundation, FIMABIS and Dr. Felipe Luna, Head of Orthopedic Surgery and Traumatology at  Málaga Central Hospital, Spain, the Second Conference of Malaga Achondroplasia Unit “Around achondroplasia – research for families” will be held in … Continue reading

April 21, 2016
by inesp.alves

Vosoritide for Achondroplasia – Rare disease day 20th April 2016

On the 20th April at 8am, NY time, Sarah Noonberg, MD, PhD, Group Vice President, Head of Global Clinical Development, presented the updates for Vosoritide. List of presented updates: 10 children, aged 6 to 11, received for 12-month a dose of 15 μg/kg/day (cohort … Continue reading

November 25, 2015
by inesp.alves
1 Comment

BioMarin investors page announces

Vosoritide for achondroplasia In June, the Company published results from the Phase 2 study showing a 50 percent or 2.01 cm/year increase in mean annualized growth velocity (speed at which growth in children occurs) in the cohort of 10 patients … Continue reading

Translate »